SK Biopharmaceuticals

Beta

KRX Filings & Disclosures 2026

Risk Factors

• • KRW ±17.1B pre-tax impact on net income for 10% USD exchange rate move in FY2025, up from KRW ±14.1B in prior year
• • Foreign exchange forward contracts total USD 118M notional to hedge currency risk as of FY2025 year-end

Management Discussion & Analysis

• • Revenue KRW 706.7B (+29% YoY), operating profit KRW 20.4B (+112%), net income KRW 25.3B (+11.5%)
• • Epilepsy drug Cenobamate (XCOPRI) sales KRW 683B (96.7% of revenue), main driver of revenue growth supported by US sales and royalties

Business Overview

• • KRW 706.7B revenue in FY2025, with Cenobamate sales accounting for 96.7% (KRW 683.0B)
• • AI-based epilepsy management solution commercialization via Mentis Care joint venture in 2025 recognized as revenue

What are the latest SK Biopharmaceuticals DART filings in 2026?

SK Biopharmaceuticals (KRX code 326030) has filed an annual report on March 18, 2026 with DART. SignalX tracks every new DART disclosure with AI-powered English summaries of business overview, risk factors, and management discussion.

When did SK Biopharmaceuticals file its most recent annual report?

SK Biopharmaceuticals filed its most recent annual report on March 18, 2026. The annual report includes audited financial statements, business overview, risk factors, and management discussion (MD&A), all available on SignalX with AI-generated English summaries and KIFRS financial data.

What is SK Biopharmaceuticals's KRX stock code?

SK Biopharmaceuticals's KRX stock code is 326030. The 6-digit stock code is the KRX standard identifier for every listed security. You can use stock code 326030 to look up all SK Biopharmaceuticals disclosures on DART, or browse them here on SignalX with AI-powered English analysis.

How often does SK Biopharmaceuticals file with DART?

Korean listed companies file an annual report once per year (typically within 90 days of fiscal year-end), a half-year report once mid-year, and quarterly reports for Q1 and Q3 — three regular periodic disclosures plus the annual. Material event reports are filed as needed when corporate events occur. SignalX monitors DART daily.

What is the difference between annual, half-year, and quarterly reports in Korea?

An annual report is a comprehensive filing with audited financials, business overview, and risk factors — analogous to the US 10-K. A half-year (interim) report covers H1 results. Quarterly reports cover Q1 or Q3 — analogous to the US 10-Q but Korea publishes only two quarterly reports per year (with the half-year report covering Q2). SignalX provides AI-generated English summaries for all three filing types for SK Biopharmaceuticals.

Where can I find SK Biopharmaceuticals financial data and KIFRS metrics?

SignalX extracts KIFRS consolidated financial data from SK Biopharmaceuticals annual reports, including revenue, gross profit, operating income, net income, total assets, stockholders' equity, EPS (basic/diluted), operating cash flow, and capital expenditure — all in KRW. Multi-year financial trends are displayed in the Financial Summary table above.